HI-Bio is a biotechnological company that develops specific antibodies to treat autoimmune and inflammatory diseases. In May 2024, HI-Bio was acquired by Biogen for $1.15 billion upfront and up to $650 million in potential milestone payments, for a total potential deal value of up to $1.8 billion.